6620 Stock Overview
A specialty pharmaceutical company, focuses on the development of drugs for various diseases in the United States and China. More details
| Snowflake Score | |
|---|---|
| Valuation | 4/6 |
| Future Growth | 0/6 |
| Past Performance | 2/6 |
| Financial Health | 6/6 |
| Dividends | 2/6 |
Handa Pharmaceuticals, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | NT$58.20 |
| 52 Week High | NT$206.00 |
| 52 Week Low | NT$56.80 |
| Beta | 1.34 |
| 11 Month Change | 0% |
| 3 Month Change | -32.56% |
| 1 Year Change | -64.94% |
| 33 Year Change | 37.75% |
| 5 Year Change | 162.16% |
| Change since IPO | -38.09% |
Recent News & Updates
Shareholder Returns
| 6620 | TW Pharmaceuticals | TW Market | |
|---|---|---|---|
| 7D | -3.6% | 1.4% | 0.8% |
| 1Y | -64.9% | 7.5% | 30.3% |
Return vs Industry: 6620 underperformed the TW Pharmaceuticals industry which returned 7.5% over the past year.
Return vs Market: 6620 underperformed the TW Market which returned 30.3% over the past year.
Price Volatility
| 6620 volatility | |
|---|---|
| 6620 Average Weekly Movement | 5.7% |
| Pharmaceuticals Industry Average Movement | 3.6% |
| Market Average Movement | 4.6% |
| 10% most volatile stocks in TW Market | 8.0% |
| 10% least volatile stocks in TW Market | 2.1% |
Stable Share Price: 6620 has not had significant price volatility in the past 3 months compared to the TW market.
Volatility Over Time: 6620's weekly volatility (6%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2014 | n/a | Toshiyo Chen | www.handapharma.com.tw |
Handa Pharmaceuticals, Inc., a specialty pharmaceutical company, focuses on the development of drugs for various diseases in the United States and China. The company provides Quetiapine XR for the treatment of Schizophrenia; and Dexlansoprazole DR capsules. It also develops ONCORE, a proprietary drug delivery technology that was developed to improve the patient compliance and safety of the tyrosine kinase inhibitor of oncology drugs; 505(b)(2)NDA, a therapeutic product; Tascenso ODT for the treatment of multiple sclerosis; and HND-033 and HND-027, an oncology products.
Handa Pharmaceuticals, Inc. Fundamentals Summary
| 6620 fundamental statistics | |
|---|---|
| Market cap | NT$8.22b |
| Earnings (TTM) | NT$452.32m |
| Revenue (TTM) | NT$972.97m |
18.2x
P/E Ratio8.4x
P/S RatioIs 6620 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 6620 income statement (TTM) | |
|---|---|
| Revenue | NT$972.97m |
| Cost of Revenue | NT$1.29m |
| Gross Profit | NT$971.68m |
| Other Expenses | NT$519.36m |
| Earnings | NT$452.32m |
Last Reported Earnings
Jun 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | 3.20 |
| Gross Margin | 99.87% |
| Net Profit Margin | 46.49% |
| Debt/Equity Ratio | 0% |
How did 6620 perform over the long term?
See historical performance and comparison